Angioslide has performed the first procedures with its new 5×300 mm Proteus device for treating the superficial femoral artery diseases. Proteus technology combines a percutaneous transluminal angioplasty balloon and embolic capture of particles in one device.
Initial treatments using the new Proteus device were conducted in Parkkrankenhaus Leipzig and Herzzentrum Bad Krozingen, both located in Germany. The Proteus 5×300 mm makes it possible to treat lesions up to 300 mm with one device, while providing an immediate solution for embolic capture.
“Angioslide’s breakthrough technology, now available also in 300 mm length as well, is a unique solution for lesions with high level of embolic material, including chronic total occlusions, in stent-restenosis, thrombus containing lesions and post atherectomy percutaneous transluminal angioplasty” said Thomas Zeller, head of the Angiology Department, Heart Center Bad-Krozingen.
Dierk Scheinert, head of the Department of Angiology, Park-Krankenhaus Leipzig added, “We have been using the Proteus product line as part of our daily practice for a few years, and are working closely with the Angioslide team. I welcome the release of the 5×300 mm. We can now use one device to treat patients with superficial femoral artery diseases, which facilitates the procedural flow and makes the intervention cost-effective.”
“We are committed to introducing new products to the market continuously, addressing the growing range of endovascular solutions,” said Lihu Avitov, Angioslide CEO. “With patients’ needs in mind, the 5×300 mm device is the first in a series of long balloons, adding to our current offering of 20-100 mm devices.”
The Proteus 5×300 mm is currently released for the European market only, and is undergoing an evaluation regulatory process with the FDA.